Liraglutide as add-on to Insulin in Type 1 Diabetes

NCT02092896 ↗

Phase 3 Completed 40 enrolled Hvidovre University Hospital Danish PhD schools of Molecular Metabolism and Endocrinology · collab Hillerod Hospital, Denmark · collab NNF Center for Basal Metabolic Research, Denmark · collab Novo Nordisk A/S · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to: Part 1: To investigate how 12 weeks treatment with liraglutide affects glycemic control in poorly controlled patients and how the treatment affects gastric emptying rate during hypoglycemia. Part 2: To investigate how 12 weeks treatment of type 1 diabetic patients with liraglutide affects counterregulatory hormones and cognitive performance during hypoglycemia.

Timeline

Start: 2013-03
Primary completion: 2014-10
Completion: 2014-10

Publications

Frandsen CS, Dejgaard TF, Holst JJ, Andersen HU, Thorsteinsson B, Madsbad S. Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study. Diabetes Care. 2015 Dec;38(12):2250-7. doi: 10.2337/dc15-1037. Epub 2015 Oct 20.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Liraglutide	Peptide	1.2 mg	—

Liraglutide as add-on to Insulin in Type 1 Diabetes

Summary

Timeline

Publications

Drugs

Indications